SCHEMBL9607630

SCHEMBL9607630

COc1c(Cl)ncnc1Nc1ccc(C#N)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCG2 Q9UNQ0 2/20 0.50
CLK1 P49759 1/20 0.48
KDM4E B2RXH2 1/20 0.47
DYRK1A Q13627 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
TTBK1 Q5TCY1 1/20 0.46
TTBK2 Q6IQ55 1/20 0.46
EGFR P00533 4/20 0.42
DHODH Q02127 1/20 0.42
KDR P35968 3/20 0.41
FLT1 P17948 1/20 0.41
CARM1 Q86X55 1/20 0.41
PRMT1 Q99873 1/20 0.41
ERBB2 P04626 1/20 0.41
ERBB3 P21860 1/20 0.41
ERBB4 Q15303 1/20 0.41
SYK P43405 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP11B1 P15538 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6917911 0.83 ABCG2 (0.48) ABCG2CLK1KDM4EDYRK1ADYRK1B
SCHEMBL6918276 0.82 NR4A1 (0.46) KDM4ETTBK1TTBK2EGFRKDR
SCHEMBL9726894 0.81 ABCG2 (0.54) ABCG2CLK1DYRK1ADYRK1BTTBK1
SCHEMBL28374004 0.80 GPR119 (0.47) EGFRKDRFLT1
SCHEMBL1232774 0.78 F9 (0.53) ABCG2CLK1KDM4ETTBK1TTBK2
SCHEMBL27962184 0.76 CA1 (0.62) EGFRKDRERBB3
SCHEMBL10120568 0.76 GPR119 (0.54) ABCG2EGFR
SCHEMBL1231113 0.75 TTBK1 (0.50) ABCG2CLK1KDM4ETTBK1TTBK2
SCHEMBL6918371 0.73 MAPK1 (0.43) TTBK1TTBK2MEN1KMT2ACYP11B1
SCHEMBL10955693 0.72 ABCG2 (0.56) ABCG2CLK1KDM4EDYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2462123-B1 4,5,6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2013-10-02 EP disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS MERCK SHARP & DOHME LLC 2012-05-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120136016-A1 4, 5, 6-TRISUBSTITUTED PYRIMIDINE DERIVATIVES AS FACTOR IXA INHIBITORS F9, F8, F12 ABCG2 632/4885CLK1 4254/4885KDM4E 1014/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.